As a brain cancer physician and a physician investigator, I could not be more excited about May being Brain Cancer Awareness Month,” says Ahluwalia in an interview with Targeted OncologyTM. Ahluwalia ...

The FDA Oncologic Drug Advisory Committee meetings on Tuesday and Wednesday discussed therapies across lymphoma, multiple myeloma, bladder cancer, and prostate cancer.

Final overall survival (OS) results from the INAVO120 trial (NCT04191499) confirmed that the addition of inavolisib (Itovebi) ...

As the oncology community prepares for the 2025 American Society of Clinical Oncology Annual Meeting, anticipation is running ...

In an interview, Aditya Shreenivas, MD, MS, discussed the approval of penpulimab in nasopharyngeal carcinoma and the study ...

AI-assisted training notably improved pathologist accuracy in HER2-low breast cancer, reducing misclassification and ...

Statin use in CLL/SLL patients showed improved survival regardless of treatment, suggesting repurposing potential for this ...

C. Ola Landgren, MD, PhD, discusses the feedback he received on minimal residual disease at this year’s Miami Myeloma MRD ...

Manmeet Ahluwalia, MD, MBA, FASCO, discussed the significance of National Cancer Research Month and highlighted how ongoing ...

Long-term data confirms early rituximab significantly delays new treatment for advanced, asymptomatic, low-burden follicular ...

INAVO120 trial shows inavolisib, palbociclib, and fulvestrant significantly improved overall survival in PIK3CA-mutant ...

In an interview, Prof Martin Dreyling discussed the approval of first-line acalabrutinib for the treatment of adult patients ...